Technology evolves in predictable life cycle stages, from early experimentation to mass adoption and, eventually, decline. Companies that successfully navigate this cycle know when to scale ...

The additions to QIAGEN’s offering of dPCR solutions for lentiviral vectors and their characterization include: The QIAcuity RCL Quant Kit detects replication-competent lentivirus (RCL), a key safety ...

The lentiviral vector market is rapidly growing, driven by advancements in gene therapy and increasing demand for innovative medical treatments. In 2023, the market was valued at USD 176.8 million and ...

Professor Amrolia selected ViroCell to manufacture the lentiviral vector for this novel CAR T-cell therapy based on its track record for delivering high quality vector. Through this relationship ...

OXB’s lentiviral vector manufacturing technology to support ... in cell and gene therapy with a mission to enable its clients to deliver life-changing therapies to patients around the world.

researchers used a lentiviral vector to deliver gene therapy to five patients with hemophilia A. After treatment, all five had stable levels of factor VIII in their blood, with no serious safety ...

SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of lentiviral vector-transduced autologous hematopoietic stem cells (HSCs ...

With a specific focus on lentiviral vector production, the Company operates a state-of-the-art, 3,000 sq. m. (32,000 sq. ft.) GMP-compliant facility in San Sebastián, Gipuzkoa, Spain. VIVEbiotech ...

Elivaldogene autotemcel (eli-cel) gene therapy, which consists of autologous CD34+ cells transduced with Lenti-D lentiviral vector containing ... Pediatric Quality of Life Inventory (PedsQL ...

The warning comes from Natalia Elizalde, PhD, chief business development officer at Spanish contract manufacturer and vector supplier VIVEbiotech, who told GEN that demand for lentiviral vectors ...

--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector ...

ROCKVILLE, Md., June 25, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced ...